Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
The study will be a dose-finding, phase I study of the combination of vorinostat and PLD in patients with advanced lymphoma refractory to at least one prior systemic therapy.
Relapsed Lymphomas|Refractory Lymphomas
DRUG: Vorinostat|DRUG: Pegylated Liposomal Doxorubicin (PLD), Doxil
Overall Response Rate, number of patients responding, end of study (up to 2 years)
The study will also be a dose-escalating study of vorinostat 200mg to 400 mg twice daily for 7 days with PLD 30mg/m2 on day 3 every 21 days, with intrapatient dose escalation.

Primary endpoint is progression. All endpoints are observational